New cabozantinib preparation for kidney cancer

Cabometyx (cabozantinib) is indicated for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx is available as film-coated tablets containing 20mg, 40mg or 60mg cabozantinib, allowing dosing at the recommended dose of 60mg once daily and also at the reduced doses recommended in case of suspected adverse drug reactions.

Cabozantinib, an inhibitor of multiple tyrosine kinases implicated in tumour growth and progression, is also available as Cometriq for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Prescribers should note that Cabometyx tablets and Cometriq capsules are not bioequivalent and should not be used interchangeably. If a patient must switch from cabozantinib capsules to tablets, they should continue at a Cabometyx dose not to exceed 60mg or the current Cometriq dose, whichever is lower.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases